VisionAir Solutions Celebrates Milestone and New Collaboration

VisionAir Solutions (VAS), the small company with a big idea for better therapeutic solutions, proudly announces a significant milestone of custom developing over 600 patient-specific airway stents using our AI VisionAir 3D Stent Software—helping save the lives of these patients.

Visionair Solutions
VisionAir Solutions Custom Airway Stents

This achievement marks the company’s commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

Utilizing its AI software and 3D printing technology, VAS has revolutionized the production of silicone airway stents—tailoring each implant to meet the unique anatomical requirements of individuals. These stents play a crucial role in enhancing respiratory function and improving the quality of life for patients with complex airway conditions; patients who were previously forced to surgically replace their “off the shelf” single lumen airway stent every 90 days can now receive a custom stent that fits their anatomy near to perfect, resulting in significant extended time before replacement.

“We are thrilled to reach this milestone,” said Randy Theken, Founder of Theken Companies. “It underscores our dedication to pushing the boundaries of what is possible in personalized medicine. Each stent represents a life-changing solution, designed by the physician and manufactured with anatomical precision, reflecting our ongoing commitment to collaboration, innovation, and patient-centered care.”

Additionally, VAS is excited to announce a strategic partnership with Lazzaro Medical. The aligned goals and innovations of both organizations revolve specifically around helping patients breathe easier. The partnership aims to advance the Tracheobronchomalacia (TBM) treatment options for both surgical and non-operative candidates. While the relationship is still in its infancy, the hope is to create industry-wide protocols for the evaluation and treatment of the millions of patients suffering from TBM.

As VAS continues to expand its 3D stent footprint and relationships, it is actively exploring new applications for its technology to include custom t-tubes and more readily available off-the-shelf patient matched airway stents (expected late 2024-early 2025).

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.